Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“NLRP3 Inhibition in Atherosclerosis: Early Clinical Signal Beyond Lipids
Targeting residual inflammatory risk has become a central challenge in contemporary cardiovascular prevention, particularly in patients who achieve optimal LDL-C control yet remain at elevated risk.
Within this framework, the NLRP3 inflammasome has emerged as a pivotal upstream regulator of vascular inflammation, orchestrating the IL-1B-IL-6-CRP signaling cascade that drives plaque progression, instability, and eventual clinical events.
Early clinical evidence with the oral NLRP3 inhibitor VTX3232 provides a compelling proof-of-concept for this therapeutic strategy.
In a randomized, double-blind phase 2a trial involving individuals with obesity and heightened cardiometabolic risk, treatment with VTX3232 led to profound reductions in inflammatory biomarkers, including up to a ~78% decrease in hsCRP and significant suppression of IL-6 levels.
Notably, these anti-inflammatory effects occurred independently of weight loss, underscoring a mechanism distinct from metabolic modulation.
When combined with semaglutide, VTX3232 demonstrated additive reductions in hsCRP, IL-6, lipoprotein(a), and fibrinogen, suggesting a complementary role alongside established cardiometabolic therapies. These findings reinforce the concept of targeting inflammation as an orthogonal axis of risk reduction.
However, current evidence remains limited to biomarker modulation, with no demonstrated impact on hard cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality.
While mechanistically robust and clinically promising, the ultimate role of NLRP3 inhibition in atherosclerosis will depend on large-scale, event-driven trials.
Reference:
- Ventyx Biosciences. Phase 2a Study of VTX3232 in Cardiometabolic Risk (ACC 2026 Presentation);
- Molecular Metabolism (2025);
- Healio Cardiology News (2026).”
More posts featuring Ney Carter Borges on Hemostasis Today.
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH
-
Oct 18, 2026, 01:44Marta Velia Antonini: How to Deliver CRRT during ECMO?
-
Oct 18, 2026, 01:19Aamir Saeed: Anticoagulation, Cirrhosis, and Other Risk Factors for Post-ERCP Bleeding
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day